Bio-Techne Corp at Stephens Investment Conference (Virtual) Transcript
I'm Jacob Johnson, the life science tools and diagnostics analyst here at Stephens. Really pleased to have the team from Bio-Techne here with us in Nashville today, including CEO Chuck Kummeth and Dave Clair from Investor Relations and Corp Dev.
Chuck, I'll turn it over to you for any opening comments you want to make, and then we'll go into Q&A.
Sure. Glad to be here. It's my first time ever in Nashville, and I wish we were located here. But Bio-Techne, where I've been here almost 9 years, it's a 40-some year old company at this point. Everyone knows R&D Systems. We, the team and I, have done a fairly good job of acquisitions and building it out over the years, but we're now -- we're still a tools company primarily, but we're expanding into diagnostics areas as well as other areas and higher forms of instrumentation.
We've got a big -- I think a big head start on cell and gene therapy workflow. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |